selected publications
- 'Secondary' acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?. Blood reviews. 2023 Review GET IT
-
Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk.
Blood research.
2022
Academic Article
GET IT
Times cited: 115 -
PD-1 inhibition in advanced myeloproliferative neoplasms.
Blood advances.
2021
Academic Article
GET IT
Times cited: 8 -
Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures.
Blood.
2021
Academic Article
GET IT
Times cited: 26 -
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.
HemaSphere.
2021
Academic Article
GET IT
Times cited: 20 - Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms. Expert review of hematology. 2020 Academic Article GET IT
-
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
Journal of hematology & oncology.
2020
Letter
GET IT
Times cited: 46 -
Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
Leukemia research.
2020
Letter
GET IT
Times cited: 16 -
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
The Lancet. Haematology.
2020
Review
GET IT
Times cited: 51 -
JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
Blood reviews.
2019
Review
GET IT
Times cited: 28 -
Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sézary Syndrome.
The Journal of investigative dermatology.
2019
Letter
GET IT
Times cited: 6 -
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Leukemia.
2019
Academic Article
GET IT
Times cited: 122 -
New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches.
Haematologica.
2019
Editorial Article
GET IT
Times cited: 13 -
Management of Intraoperative Coagulopathy.
Neurosurgery clinics of North America.
2018
Review
GET IT
Times cited: 5 -
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism.
Journal of cellular and molecular medicine.
2018
Academic Article
GET IT
Times cited: 12 -
MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.
Leukemia.
2017
Academic Article
GET IT
Times cited: 52 -
Extended Small-Dose Platelet Transfusions in Multitransfused Hemato-Oncological Patients: A Single-Center Experience.
Acta haematologica.
2017
Academic Article
GET IT
Times cited: 3 -
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
British journal of haematology.
2017
Academic Article
GET IT
Times cited: 22 -
Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.
Blood.
2016
Academic Article
GET IT
Times cited: 71 -
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Blood.
2015
Academic Article
GET IT
Times cited: 27 -
High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?.
Hematological oncology.
2015
Academic Article
GET IT
Times cited: 11 -
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Blood.
2014
Academic Article
GET IT
Times cited: 448 -
Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.
American journal of hematology.
2014
Academic Article
GET IT
Times cited: 13 -
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.
Blood.
2014
Academic Article
GET IT
Times cited: 35 -
Immunotherapy for multiple myeloma.
Expert review of hematology.
2014
Review
GET IT
Times cited: 10 -
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013
Academic Article
GET IT
Times cited: 75 -
Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?.
Current cancer drug targets.
2013
Review
GET IT
Times cited: 10 -
Early death in patients diagnosed with non-Hodgkin's lymphoma.
Annals of hematology.
2012
Academic Article
GET IT
Times cited: 13 -
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
Genes & cancer.
2012
Academic Article
GET IT
Times cited: 72 -
STAT signaling in the pathogenesis and treatment of myeloid malignancies.
JAK-STAT.
2012
Review
GET IT
Times cited: 171 -
Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.
Leukemia.
2011
Letter
GET IT
Times cited: 32 -
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
Blood.
2011
Academic Article
GET IT
Times cited: 219 -
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Proceedings of the National Academy of Sciences of the United States of America.
2009
Academic Article
GET IT
Times cited: 270 -
Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
The Israel Medical Association journal : IMAJ.
2006
Editorial Article
GET IT
Times cited: 5 -
Confirmation of the association between male pattern baldness and the androgen receptor gene.
European journal of dermatology : EJD.
2005
Academic Article
GET IT
Times cited: 51 -
Sternoclavicular infectious arthritis in previously healthy adults.
Seminars in arthritis and rheumatism.
2002
Review
GET IT
Times cited: 57